Metformin Recall Issued By Bayshore Pharmaceuticals Due To High Levels Of NDMA

Amid the continuing discovery of problems with metformin pills contaminated with cancer-causing chemicals, federal regulators have announced another major recall for the generic diabetes drug, due to the presence of high levels of N-nitrosodimethylamine (NDMA) in pulls manufactured and sold by Bayshore Pharmaceuticals.

The FDA announced the latest metformin recall on August 20, following the detection of NDMA in Bayshore 500 mg and 750 mg extended release tablets.

NDMA is considered a human carcinogen, which can be a byproduct of the drug manufacturing process or from inherent processes associated with certain pharmaceutical ingredients.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In recent years, detection of the chemical has resulted in widespread Zantac recalls and valsartan recalls, and users of the popular heartburn and blood pressure medications have reported developing various types of cancer following long-term use, including breast cancer, bladder cancer, stomach cancer, testicular cancer and other injuries.

This latest recall affects two lots of generic metformin distributed by Bayshore Pharmaceuticals, including Metformin Hydrocholoride Extended-Release Tablets USP in 500 mg strength, sold in 1,000-count bottles with a lot number of 18641 and an NDC Number of 76385-128-10; and Metformin Hydrochloride Extended-Release Tablets USP in 750 mg strength, sold in 100-count bottles with a lot number of 18657 and an NDC Number of 76385-129-01. Both lots have expiration dates of May 2021.

The pills were manufactured by Bexico Pharmaceuticals Limited, in Bangladesh in June 2019, and were distributed in the U.S. by Bayshore, who then sold the lots to wholesalers and distributors.

Metformin NDMA Problems

In December 2019, reports first warned about the potential risk of metformin NDMA contamination problems, after some versions of the drug sold outside the United States tested positive for the chemical, raising concerns that metformin recalls may be necessary. However, the FDA indicated at that time that testing of products distributed in the U.S. found that the NDMA levels in metformin were undetectable or below federal limits for exposure to the chemical.

In March 2020, the independent online pharmacy Valisure filed a citizen’s petition urging the FDA to recall metformin, after independent testing found levels of NDMA in certain pills was higher than the agency’s recommended daily exposure threshold of 96 nanograms.

Since then, the FDA says it has confirmed some of the Valisure findings, resulting in a number of separate recalls as specific lots of the medication have been found to contain higher than acceptable levels of NDMA.

Since the recalls began, a number of consumers have filed metformin NDMA lawsuits, indicating they developed cancer as a result of taking the tainted diabetes medication.

Bayshore indicates it is informing its customers of the recall by phone and through the recall notification. The company is currently arranging for the return of the recalled products and advises anyone with the affected lots quarantine them immediately.

Customers and patients with questions or who wish to report adverse events or quality issues can call Bayshore Pharmaceuticals LLC at 877-372-6093. Those wishing to return affected products can contact the company’s recall processor, Qualanex, LLC for instructions and a return kit by calling 888-504-2013.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.